CA3254598A1 — Non-linear dosing of mirdametinib
Assigned to SpringWorks Therapeutics Inc · Expires 2023-09-21 · 3y expired
What this patent protects
The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas iPN>, plexiform neurofibromas associated with neurofibromatosis type I (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceu…
USPTO Abstract
The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas iPN>, plexiform neurofibromas associated with neurofibromatosis type I (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.